Medullary thyroid cancer natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 3: Line 3:
{{CMG}}; {{AE}} {{Ammu}}
{{CMG}}; {{AE}} {{Ammu}}
==Overview==
==Overview==
If left untreated, patients with medullary thyroid cancer may progress to develop [[metastasis]]. Common complications of medullary thyroid cancer include vocal cord compression, [[dysphagia]], and [[dyspnea]]. The presence of [[metastasis]] is associated with a particularly poor prognosis among patients with medullary thyroid cancer. The 5-year event-free survival rate is 80%.
If left untreated, patients with medullary thyroid cancer may progress to develop [[metastasis]]. Common [[complications]] of medullary thyroid cancer include [[vocal cord]] compression, [[dysphagia]], and [[dyspnea]]. The presence of [[metastasis]] is associated with a particularly poor [[prognosis]] among patients with medullary thyroid cancer. The 5-year event-free survival rate is 80%.
==Natural History==
==Natural History==
* The symptoms of sporadic medullary thyroid cancer usually develop in the fifth and sixth decade of life and start with a nodule in the upper lobe of the thyroid.<ref name="pmid6503683">{{cite journal |vauthors=Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS, Hickey RC, Samaan NA |title=Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients |journal=Medicine (Baltimore) |volume=63 |issue=6 |pages=319–42 |date=November 1984 |pmid=6503683 |doi= |url=}}</ref>
* The symptoms of sporadic medullary thyroid cancer usually develop in the fifth and sixth decade of life and start with a [[nodule]] in the upper lobe of the [[thyroid]].<ref name="pmid6503683">{{cite journal |vauthors=Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS, Hickey RC, Samaan NA |title=Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients |journal=Medicine (Baltimore) |volume=63 |issue=6 |pages=319–42 |date=November 1984 |pmid=6503683 |doi= |url=}}</ref>
* In 50% of the patients, the initial presentation may be metastatic cervical adenopathy.  
* In 50% of the [[patients]], the initial presentation may be metastatic cervical [[adenopathy]].  
* Symptoms of adjacent structures compression or invasion may manifest in 15% of the patients.  
* [[Symptoms]] of adjacent structures compression or invasion may manifest in 15% of the [[patients]].  
* Without treatment, the patient will develop symptoms of [[metastasis]] such as to lungs and/or bones, which may eventually lead to death.  
* Without treatment, the [[patient]] will develop [[symptoms]] of [[metastasis]] such as to [[lungs]] and/or [[bones]], which may eventually lead to death.  
==Complications==
==Complications==
* [[Metastases]] to [[lung]], [[bone]]s, [[liver]], and [[brain]]<ref name="pmid6503683">{{cite journal |vauthors=Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS, Hickey RC, Samaan NA |title=Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients |journal=Medicine (Baltimore) |volume=63 |issue=6 |pages=319–42 |date=November 1984 |pmid=6503683 |doi= |url=}}</ref>
* Possible [[complications]] of medullary thyroid cancer include:
* Hypocalcemia after [[surgery]] due to [[parathyroid]] removal
**[[Metastases]] to [[lung]], [[bone]]s, [[liver]], and [[brain]]<ref name="pmid6503683">{{cite journal |vauthors=Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS, Hickey RC, Samaan NA |title=Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients |journal=Medicine (Baltimore) |volume=63 |issue=6 |pages=319–42 |date=November 1984 |pmid=6503683 |doi= |url=}}</ref>
* [[Dysphagia]]
** Hypocalcemia after [[surgery]] due to [[parathyroid]] removal
* Hoarseness
** [[Dysphagia]]
* [[Diarrhea]]
** Hoarseness
* [[Cushing's syndrome]]
** [[Diarrhea]]
** [[Cushing's syndrome]]
 
==Prognosis==
==Prognosis==
* Medullary thyroid cancer prognosis depends on the stage of the disease at the time of diagnosis.<ref name="HundahlFleming1998">{{cite journal|last1=Hundahl|first1=Scott A.|last2=Fleming|first2=Irvin D.|last3=Fremgen|first3=Amy M.|last4=Menck|first4=Herman R.|title=A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995|journal=Cancer|volume=83|issue=12|year=1998|pages=2638–2648|issn=0008-543X|doi=10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1}}</ref>
* Medullary thyroid cancer [[prognosis]] depends on the [[stage]] of the [[disease]] at the time of [[diagnosis]].<ref name="HundahlFleming1998">{{cite journal|last1=Hundahl|first1=Scott A.|last2=Fleming|first2=Irvin D.|last3=Fremgen|first3=Amy M.|last4=Menck|first4=Herman R.|title=A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995|journal=Cancer|volume=83|issue=12|year=1998|pages=2638–2648|issn=0008-543X|doi=10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1}}</ref><ref name="RomanLin2006">{{cite journal|last1=Roman|first1=Sanziana|last2=Lin|first2=Rong|last3=Sosa|first3=Julie Ann|title=Prognosis of medullary thyroid carcinoma|journal=Cancer|volume=107|issue=9|year=2006|pages=2134–2142|issn=0008543X|doi=10.1002/cncr.22244}}</ref>
* The 5-year relative survival rate is 93% for stage I to III.
* The 5-year relative [[survival rate]] is 93% for stage I to III.
* The 5-year survival rate for stage IV is 28%.
* The 5-year [[survival rate]] for stage IV is 28%.
* Medullary thyroid cancer is associated with a 5-year survival rate of 86% and 10-year survival rate of 65%.
* Medullary thyroid cancer is associated with a 5-year [[survival rate]] of 86% and 10-year survival rate of 65%.
* By overall [[cancer staging]] into stages I to IV, the 5-year survival rate is 100% at [[cancer staging|stage]] I, 98% at stage II, 81% at stage III and 28% at stage IV.<ref name=acc>[http://www.cancer.org/cancer/thyroidcancer/detailedguide/thyroid-cancer-survival-rates cancer.org > Thyroid Cancer] By the American Cancer Society. In turn citing: AJCC Cancer Staging Manual (7th ed).</ref> The prognosis of medullary thyroid cancer is poorer than that of follicular and papillary thyroid cancer when it has metastasized (spread) beyond the thyroid gland.
* The prognostic value of measuring [[calcitonin]] and [[carcinoembryonic antigen]] (CEA) concentrations in the blood was studied in 65 medullary thyroid cancer patients who had abnormal [[calcitonin]] levels after [[surgery]] (total [[thyroidectomy]] and [[lymph node]] dissection).<ref name=Barbet>{{cite journal |author=Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF |title=Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma |journal=J. Clin. Endocrinol. Metab. |volume=90 |issue=11 |pages=6077–84 |year=2005 |pmid=16091497 |doi=10.1210/jc.2005-0044|url=http://jcem.endojournals.org/cgi/pmidlookup?view=long&pmid=16091497}}</ref>   The prognosis correlated with the rate at which the postoperative calcitonin concentration doubles, termed the calcitonin doubling time (CDT), rather than the pre- or postoperative absolute calcitonin level:
*'''CDT less than 6 months:'''  3 patients out of 12 (25%) survived 5 years.  1 patient out of 12 (8%) survived 10 years. All died within 6 months to 13.3 years.
*'''CDT between 6 months and 2 years:'''  11 patients out of 12 (92%) survived 5 years.  3 patients out of 8 (37%) survived 10 years.  4 patients out of 12 (25%) survived to the end of the study.
*'''CDT more than 2 years:''' 41 patients out of 41 (100%) were alive at the end of the study.  These included 1 patient whose calcitonin was stable and 11 patients who had decreasing calcitonin levels.
* The [[calcitonin]] doubling time was a better predictor of MTC survival than [[Carcinoembryonic antigen|CEA]]<ref name=Barbet/> but following both tests is recommended.<ref name=NCCN>Thyroid Carcinoma. NCCN guidelines. http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf</ref><ref>ASCO SEP 3rd edition<!--expand ref--></ref>


==References==
==References==

Latest revision as of 19:43, 3 September 2019

Medullary thyroid cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Medullary thyroid cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Medullary thyroid cancer natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Medullary thyroid cancer natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Medullary thyroid cancer natural history, complications and prognosis

CDC on Medullary thyroid cancer natural history, complications and prognosis

Medullary thyroid cancer natural history, complications and prognosis in the news

Blogs on Medullary thyroid cancer natural history, complications and prognosis

Directions to Hospitals Treating Medullary thyroid cancer

Risk calculators and risk factors for Medullary thyroid cancer natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

If left untreated, patients with medullary thyroid cancer may progress to develop metastasis. Common complications of medullary thyroid cancer include vocal cord compression, dysphagia, and dyspnea. The presence of metastasis is associated with a particularly poor prognosis among patients with medullary thyroid cancer. The 5-year event-free survival rate is 80%.

Natural History

  • The symptoms of sporadic medullary thyroid cancer usually develop in the fifth and sixth decade of life and start with a nodule in the upper lobe of the thyroid.[1]
  • In 50% of the patients, the initial presentation may be metastatic cervical adenopathy.
  • Symptoms of adjacent structures compression or invasion may manifest in 15% of the patients.
  • Without treatment, the patient will develop symptoms of metastasis such as to lungs and/or bones, which may eventually lead to death.

Complications

Prognosis

References

  1. 1.0 1.1 Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS, Hickey RC, Samaan NA (November 1984). "Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients". Medicine (Baltimore). 63 (6): 319–42. PMID 6503683.
  2. Hundahl, Scott A.; Fleming, Irvin D.; Fremgen, Amy M.; Menck, Herman R. (1998). "A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995". Cancer. 83 (12): 2638–2648. doi:10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1. ISSN 0008-543X.
  3. Roman, Sanziana; Lin, Rong; Sosa, Julie Ann (2006). "Prognosis of medullary thyroid carcinoma". Cancer. 107 (9): 2134–2142. doi:10.1002/cncr.22244. ISSN 0008-543X.


Template:WikiDoc Sources